| Literature DB >> 35974308 |
Zun Wu1, Yating Wu1, Haofeng Gao1, Xuexin He1, Qiang Yao1, Zhanglei Yang1, Jinyi Zhou1, Linting Ji1, Jinwei Gao1, Xuying Jia1, Yong Dou1, Xiaoyu Wang2, Peng Shao3.
Abstract
Vibrio vulnificus is a pathogenic bacterium that causes disease in marine fish, affecting fish farming and human health worldwide. In May 2021, in the Bohai Bay region, a disease broke out in commercially farmed pearl gentian grouper (♀Epinephelus fuscoguttatus × ♂Epinephelus lanceolatus), causing huge economic losses. The diseased fish had skin lesions, water accumulation in their abdomens, and showed tissue and organ damage. V. vulnificus biotype 2 has been reported in eels and other marine fish, but it is less reported in pearl gentian grouper. In this study, the pathogenic strain isolated from diseased fish was identified as V. vulnificus EPL 0201 biotype 2 on the basis of physiological and biochemical characteristics and the results of 16S rRNA gene and gyrB sequencing, virulence gene detection, and recursive infection experiments. To gain a comprehensive understanding of the pathogenicity and drug resistance of this strain, whole-genome sequencing was performed. Whole-genome analysis showed that the gene map of this strain was complete. The Virulence Factor Database annotation results showed that this strain had the key virulence factor genes vvhA and rtxA, which cause host disease. In addition, this strain had genes conferring resistance against cephalosporins, aminoglycosides, tetracyclines, and sulfonamides. Antimicrobial susceptibility testing confirmed the presence of these resistance genes identified in the genome. The results of this study show that V. vulnificus EPL 0201 biotype 2 is a multi-drug resistant strain with high pathogenicity.Entities:
Keywords: Antimicrobial susceptibility; Pearl gentian grouper; Vibrio vulnificus; Virulence genes; Whole-genome sequencing
Mesh:
Substances:
Year: 2022 PMID: 35974308 PMCID: PMC9380395 DOI: 10.1186/s12866-022-02610-1
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 4.465
Fig. 1Varying morphology and flagella of strain EPL 0201 observed under light and electron microscopes. A Micro-curved rod-shaped bacteria (black arrow). B Micro-curved rod-shaped bacteria and flagella observed under an electron microscope
Fig. 2Molecular identification and virulence gene detection of strain EPL 0201. A Phylogenetic tree of Vibrio spp. based on the 16S rRNA gene sequence constructed using the neighbor-joining method. Bootstrap values were based on 1000 replicates, and percentage bootstrap values are shown at each node. B Phylogenetic tree of Vibrio spp. based on gyrB sequence constructed using the neighbor-joining method. Bootstrap values were based on 1000 replicates, and percentage bootstrap values are shown at each node. C Agarose gel electrophoresis did not show the presence of vcgC and OmpU but showed the presence of vvhA, rtxA, and Wza in the PCR products. M, Marker; Neg, negative control. Original agarose gel electropherogram (Supplementary Fig. S6)
Physiological and biochemical characteristics of pathogenic strain EPL 0201 and other V. vulnificus strains
| Characteristics 1 | EPL 0201 1 | ||
|---|---|---|---|
| Gram nature | − | − | − |
| Hemolysis | β | β | β |
| Motility | + | + | + |
| Oxidase | + | + | + |
| Catalase | + | + | + |
| ONPG | + | + | + |
| Arginine dihydrolase | − | − | − |
| Lysine decarboxylase | + | + | + |
| Ornithine decarboxylase | − | − | + |
| Nitrate reduction | + | + | + |
| H2S production | − | − | − |
| Indole production | − | − | + |
| Urease | − | − | − |
| Voges–Proskauer | − | − | − |
| Gelatinase | + | + | + |
| Oxidative fermentation | F | F | F |
| Glucose | + | + | + |
| Arabinose | − | − | − |
| Inositol | − | − | − |
| Mannitol | − | − | + |
| Sorbitol | − | − | − |
| Sucrose | − | − | − |
| Rhamnose | − | − | − |
| Melibiose | − | − | − |
| Amygdalin | − | − | − |
| Growth on TCBS | G | G | G |
| Growth in 0% NaCl | − | − | − |
| Growth in 3% NaCl | + | + | + |
| Growth in 6% NaCl | + | + | + |
| Growth in 7% NaCl | + | + | + |
| Growth in 8% NaCl | − | − | − |
| Growth in 10% NaCl | − | − | − |
| Growth at 42℃ | − | − | + |
| O/129 (10 μg) | S | S | S |
| O/129 (150 μg) | − | − | + |
Note: + Positive, − Negative, β β-hemolytic, G Colonies grow green on TCBS, S Sensitive, ONPG Ortho-nitrophenyl-β-galactoside
Fig. 3Symptoms of fish tested for recursive infection. A Body chart of experimental fish in control group. B Abdominal cavity of fish in control group (white arrow). C Phosphorus loss in a large area of the skin (white arrow). D Hemorrhagic necrosis of the liver (aa white arrow); a large amount of fluid in the abdominal cavity (ab white arrow); and intestinal inflammation (ac white arrow). E Agarose gel electrophoresis of PCR products of vvhA and rtxA from the suspected V. vulnificus isolates. M, Marker (unit, bp); 1–4, PCR products of vvhA from V. vulnificus in samples from four diseased fishes in the 1 × 107–1 × 104 CFU mL−1 groups; 5–8, PCR products of rtxA from V. vulnificus in samples from 4 diseased fishes in the 1 × 107–1 × 104 CFU mL.−1 groups; 9, negative control; 10–11, positive control (PCR products of vvhA and rtxA from EPL 0201 isolate). Original agarose gel electropherogram (Fig. S6)
Results of recursive infection test following intraperitoneal injection
| 1 | 12 | 1.0 × 107 | 0.1 | 100% | |
| 2 | 12 | 1.0 × 106 | 0.1 | 83% | |
| 3 | 12 | 1.0 × 105 | 0.1 | 58% | |
| 4 | 12 | 1.0 × 104 | 0.1 | 25% | |
| 5 | 12 | 1.0 × 103 | 0.1 | 0% | |
| 6 | 12 | 0.85% NaCl (control) | 0.1 | 0% |
Fig. 4GC content and average depth correlation analysis chart. Note: The outermost circle represents the genome size, with each scale being 5 kb. The second circle and the third circle represent genes on the positive and negative strands of the genome. The different colors represent different COG functional classifications. The fourth circle represents a repetitive sequence, the fifth circle represents tRNA (blue) and rRNA (purple), and the sixth circle represents the GC content. The light yellow part indicates that the GC content of the region is higher than the average GC content of the genome, whereas the blue part indicates that the GC content of the region is lower than the average GC content of the genome. The higher the peak value, the greater the difference in GC content. The innermost circle represents GC skew, wherein the dark gray parts represent the regions where the G content is greater than the C content and the red parts represent the regions where the C content is greater than the G content
Fig. 5Species distribution map of the results of sequence alignment using the NR database. Note: Different colors represent different species
VFDB annotation statistics
| Gene | Gene ID | VFDB ID | Category | E-value | Score | Function |
|---|---|---|---|---|---|---|
| GE003721 | VF0611 | Exotoxin | 2.47E-189 | 612 | Associated with enhanced growth in vivo and tissue necrosis in the small intestine | |
| rtxA | GE004057 | VF0265 | Exotoxin | 0E | 4372 | Induces cytopathic activities in host cells |
| GE002755 | VF0465 | Immune modulation | 5.96E-160 | 457 | Plays an important role in protecting bacteria from the host’s innate immune response |
Note: “E-value” represents the expected value of the functional annotation results (the smaller the value, the more credible the results); “Score” represents the comprehensive score of the sequence alignment
CARD database annotation statistics
| Gene | Gene ID | ARO ID | Resistance | Resistance Mechanism |
|---|---|---|---|---|
| GE001452 | 3,000,676 | Penam, macrolide, cephalosporin, cephamycin, tetracycline, and fluoroquinolone | Antibiotic efflux | |
| GE000225 | 3,000,518 | Penam, macrolide, and fluoroquinolone | Antibiotic efflux | |
| GE004010 | 3,000,777 | Tetracycline and fluoroquinolone | Antibiotic efflux | |
| GE005069 | 3,002,705 | Phenicol | Antibiotic efflux | |
| GE005065 | 3,004,441 | Tetracycline | Antibiotic efflux | |
| GE002506 | 3,004,446 | Carbapenem, cephalosporin, monobactam, penam, and cephamycin | Antibiotic target alteration | |
| GE002526 | 3,003,316 | Fluoroquinolone | Antibiotic target alteration | |
| GE000717 | 3,003,324 | Peptide | Antibiotic target alteration | |
| GE005011 | 3,000,410 | Sulfone and sulfonamide | Antibiotic target replacement | |
| GE005074 | 3,000,412 | Sulfone and sulfonamide | Antibiotic target replacement | |
| GE003041 | 3,004,289 | Carbapenem | Antibiotic inactivation | |
| GE005072 | 3,002,660 | Aminoglycoside | Antibiotic inactivation | |
| GE005073 | 3,002,639 | Aminoglycoside | Antibiotic inactivation | |
| GE005009 | 3,002,616 | Aminoglycoside | Antibiotic inactivation | |
| GE005007 | 3,002,848 | Rifamycin | Antibiotic inactivation | |
| GE005062 | 3,000,873 | Penam, penem, cephalosporin, and monobactam | Antibiotic inactivation |
Note: “ARO ID” represents the antibiotic resistance gene ID of the gene annotated into the database, “Resistance” represents the name of the antibiotic that caused the resistance, “Resistance Mechanism” represents the resistance mechanism of the resistance gene
Antimicrobial susceptibility testing of the pathogenic strain EPL 0201
| Group | Name | Drug concentration | Bacteriostatic ring diameter | Sensitivity† |
|---|---|---|---|---|
| β-Lactams | Cefazolin | 30 | 17.66 | R |
| Cephalothin | 30 | 15.98 | I | |
| Cefotaxime | 30 | 15.43 | R | |
| Ceftriaxone | 30 | 31.02 | S | |
| Ceftazidime | 30 | 20.26 | I | |
| Cefoperazone | 75 | 26.74 | S | |
| Cefepime | 30 | 21.26 | S | |
| Cefoxitin | 30 | 15.68 | R | |
| Amoxicillin | 10 | 11.52 | R | |
| Azlocillin | 75 | 16.36 | R | |
| Piperacillin | 100 | 21.28 | S | |
| Mezlocillin | 75 | 20.64 | S | |
| Ticarcillin | 75 | 23.26 | S | |
| Ampicillin | 10 | 10.16 | R | |
| Penicillin | 10 | 8.66 | R | |
| Imipenem | 10 | 29.72 | S | |
| Meropenem | 10 | 31.72 | S | |
| Aminoglycosides | Kanamycin | 30 | 17 | I |
| Spectinomycin | 100 | 15.26 | I | |
| Neomycin | 30 | 19.12 | I | |
| Streptomycin | 10 | 6.35 | R | |
| Amikacin | 30 | 13.88 | R | |
| Gentamicin | 10 | 16.71 | S | |
| Tobramycin | 10 | 15.64 | S | |
| Glycopeptides | Teicoplanin | 30 | 8.67 | R |
| Vancomycin | 30 | 10.65 | R | |
| Quinolones | Nalidixic acid | 30 | 36.51 | S |
| Ciprofloxacin | 5 | 18.68 | I | |
| Levofloxacin | 5 | 25.03 | S | |
| Enrofloxacin | 5 | 34.9 | S | |
| Norfloxacin | 10 | 11.66 | R | |
| Ofloxacin | 5 | 15.54 | I | |
| Chloramphenicols | Chloramphenicol | 30 | 16.98 | I |
| Macrolides | Azithromycin | 15 | 31.37 | S |
| Erythromycin | 15 | 29.06 | S | |
| Roxithromycin | 15 | 23.01 | S | |
| Midecamycin | 15 | 24.43 | S | |
| Claricid | 15 | 23.16 | S | |
| Nitrofurans | Furazolidone | 300 | 21.5 | S |
| Lincosamides | Lincomycin | 2 | 10.02 | R |
| Clindamycin | 2 | 13.96 | I | |
| Sulfonamides | Trimethoprim | 23.75 | 6.35 | R |
| Tetracyclines | Tetracycline | 30 | 15.04 | I |
| Doxycycline | 30 | 18.86 | I | |
| Minocycline | 30 | 32.77 | S | |
| Others | Rifampin | 5 | 11.98 | R |
| Methoxyamine | 5 | 6.35 | R | |
| Polymyxin B | 300 | 11.03 | I |
Note: “blank” means no inhibition zone, “S” means highly sensitive, “I” means moderately sensitive; and “R” means resistant